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Abstract
Background: Southeast Asia is a region with great potential for the emergence of a pandemic influenza virus. Global efforts
to improve influenza surveillance in this region have documented the burden and seasonality of influenza viruses and have
informed influenza prevention strategies, but little information exists about influenza vaccination guidelines and vaccine
sales.
Methods: To ascertain the existence of influenza vaccine guidelines and define the scope of vaccine sales, we sent
a standard three-page questionnaire to the ten member nations of the Association of Southeast Asian Nations. We also
surveyed three multinational manufacturers who supply influenza vaccines in the region.
Results: Vaccine sales in the private sector were ,1000 per 100,000 population in the 10 countries. Five countries reported
purchasing vaccine for use in the public sector. In 2011, Thailand had the highest combined reported rate of vaccine sales
(10,333 per 100,000). In the 10 countries combined, the rate of private sector sales during 2010–2011 (after the
A(H1N1)2009pdm pandemic) exceeded 2008 pre-pandemic levels. Five countries (Indonesia, Malaysia, Singapore, Thailand
and Vietnam) had guidelines for influenza vaccination but only two were consistent with global guidelines. Four
recommended vaccination for health care workers, four for elderly persons, three for young children, three for persons with
underlying disease, and two for pregnant women.
Conclusions: The rate of vaccine sales in Southeast Asia remains low, but there was a positive impact in sales after the
A(H1N1)2009pdm pandemic. Low adherence to global vaccine guidelines suggests that more work is needed in the policy
arena.
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Introduction
Influenza is one of the world’s most prevalent vaccine prevent-
able diseases, responsible for three to five million cases of severe
illness and 250 to 500 thousand deaths annually [1]. Over the past
10 years, there has been an increased focus on establishing more
robust surveillance for influenza viruses globally with a heavy
emphasis on tropical and subtropical Southeast Asia. Resources,
including more than $1 billion from the United States government
since 2005 [2], have been preferentially applied to Southeast Asia
because of the emergence and persistence of avian influenza A
(H5N1) and concern that the region is a ‘‘hotspot’’ for the
evolution of other influenza viruses [3]. As demonstrated by H5N1
and the 2009 pandemic caused by the A(H1N1)2009pdm virus,
investing in prevention and preparedness strategies is essential for
all countries in the region. Moreover, given the increasing trend
toward urbanization in Asia [4], the resulting evolution of mega
cities, and the ease of modern air travel, the spread of a lethal
pandemic influenza virus is a very real possibility and cause for
continued concern.
Until recently, use of seasonal influenza vaccine was extremely
uncommon in Southeast Asia. For example, doses were primarily
limited to the private sector or allotted for pilgrims to the Hajj [5].
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The emergence of H5N1 and the A(H1N1)2009pdm virus,
together with more country-specific data on the burden of disease,
may have increased vaccine uptake in some countries, a pattern
previously observed among European nations [6]. However,
established vaccination guidelines and the extent of vaccine use
have not been well documented. Given the shared global priority
to improve access and affordability to influenza vaccines globally
[7], as well as the 2012 Strategic Advisory Group of Experts
(SAGE) on immunization recommendations for seasonal influenza
vaccine, [8] our objectives were to compare country-specific
published vaccine guidelines to the SAGE recommendations and
report seasonal influenza vaccine sales data in Southeast Asia from
2008–2011.
Materials and Methods
Ethics Statement
The protocol was reviewed by the U.S. CDC and determined to
be exempt from review by the Institutional Review Board. It was
not reviewed by any other ethics board.
Selected economic and health indicators for the ten countries
were obtained from publically available websites cited in the
footnotes of Table 1. To obtain data on vaccine guidelines and
vaccine sales data we electronically sent a standard three-page
questionnaire to Ministries of Health in the ten Southeast Asian
countries in the Association of Southeast Asian Nations [ASEAN:
Brunei, Cambodia, Indonesia, Lao People’s Democratic Republic
(PDR), Malaysia, the Republic of the Union of Myanmar
(Myanmar), Philippines, Singapore, Thailand, and Vietnam].
We asked about formal guidelines for use of seasonal influenza
vaccine, whether influenza vaccine was routinely used in the
public sector (defined as purchased by the government and
provided free of charge to citizens), the number of doses of vaccine
imported from 2008 through 2011, and the presence of domestic
capacity to produce human influenza vaccine. We also asked
about receipt of purchased or donated monovalent
A(H1N1)pdm09 vaccine in 2009 and 2010 and supplemented
these data with publically available data about donated vaccine
[9].
To better ascertain the total number of influenza vaccine doses
sold to each country, we surveyed three multinational manufac-
turers. Globally, seven multinational manufactures produced 70%
of seasonal influenza vaccine in 2009–2010 [10]. However, several
of these large producers mainly serve a domestic market (not in
ASEAN) and one has limited sales to Asia due to the high cost of
the vaccine. It is estimated that the three manufacturers we
surveyed supply .87% of the market share of influenza vaccine in
the region (Mark Simmerman, Sanofi Pasteur Asia Pacific Medical
Affairs, personal communication). The companies provided us
with the number of doses of vaccines sold in the private sector in
each country for the years 2008–2011 (data from one company
were only through August 2011). Data were aggregated across the
companies for confidentiality purposes, and data for Brunei/
Malaysia and Cambodia/Lao PDR/Myanmar/Thailand/Viet-
nam were only provided in aggregate from some manufacturers.
Sales figures are presented as rates per 100,000 persons using
population data from the United Nations [11]. Data were entered
in STATA version 11 (STATA, College Station, TX, USA).
Results
The 10 ASEAN countries differed widely across the economic
and health spectrum (Table 1). Two were high income countries, 6
middle income, and 2 low income. Total health expenditures as
a percent of gross domestic product did not correlate with income
classification. Under 5-year mortality rates were inversely corre-
lated to income, with the highest rates in the low income countries.
Geographically, these countries span from 9o south to 22o north of
the equator. Of the ten countries contacted, nine (90%, all except
Brunei) responded to our survey.
Vaccine Sales in the Private Sector
Doses of vaccine sold to the private sector per 100,000 persons
varied by country and year (Table 2). Among the four countries
Table 1. Selected health, budgetary, and immunization statistics of the ten Southeast Asian countries surveyed.
Country
GNI per capita,
international $1
Country income
classification2
Total expenditure on
health as % GDP1
% routine3 childhood
vaccines funded by
government4
Under 5 child
mortality rate per
1000 live births4
% of deaths among
children ,5 years
caused by
pneumonia1
Singapore 55,790 High 4.0 100 3 7% (5th)
Brunei 50,180 High 2.8 100 7 5% (5th)
Malaysia 14,220 Upper-middle 4.4 80 6 6% (5th)
Thailand 8,190 Upper-middle 3.9 100 13 9% (4th)
Indonesia 4,200 Lower-middle 2.6 100 35 14% (3rd)
Philippines 3,980 Lower-middle 3.6 100 29 16% (3rd)
Vietnam 3,070 Lower-middle 6.8 30 23 12% (4th)
Lao PDR 2,440 Lower-middle 4.5 6 54 19% (2nd)
Cambodia 2,080 Low 5.6 23 51 16% (3rd)
Myanmar 1,950 Low 2.0 0 66 17% (3rd)
GNI: Gross National Income; DGP: Gross Domesitc Product; USD: United States Dollars.
1Total gross national income per-capita, total expenditure on health, percent of deaths among children ,5 years caused by pneumonia and ranking of pneumonia as
the cause of childhood mortality updated May 2012 and found at: levels for each country found at: http://www.who.int/countries/en/.
2World Bank country classification can be found at: http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
3Routine childhood vaccinations are tuberculosis (BCG), diptheria, tetanus, pertussis (DTP), oral polio vaccine (OPV), hepatitis B, and measles-containing vaccine (MCV).
4Percent of routine vaccinations funded by government and under 5-year mortality rates updated Oct 2012 and found at: http://apps.who.int/immunization_
monitoring/en/globalsummary/countryprofileselect.cfm.
doi:10.1371/journal.pone.0052842.t001
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with non-aggregated data, the lowest rates (,200 per 100,000
persons) were consistently observed in Indonesia, a lower-middle
income country. Singapore, a high income country, had the
highest rates in 2008 (7034 per 100,000) and 2009 (12078 per
100,000). In 2010, Thailand, an upper-middle income country,
surpassed Singapore (6910 vs. 6047 per 100,000) but Singapore
was again highest in 2011 (7285 vs. 4943 per 100,000 persons).
The aggregate rate of private sales in the 10 countries increased
from 481 per 100,000 in 2008 to 954 per 100,000 in 2009 and the
increase was sustained in 2010 and 2011 after the pandemic
(Table 2).
Vaccine Sales in the Public Sector
Cambodia, Lao PDR and Vietnam, all low or lower-middle
income countries, reported that no seasonal influenza vaccine was
purchased by the government for use in the public sector during
2008 through mid-2011 (Table 2). The same was true for
Singapore where influenza vaccines are routinely offered in public
hospitals but are not free of charge. Malaysia (for use in healthcare
workers), Indonesia and Myanmar purchased vaccine for use in
the public sector but did not report the number of doses. The
Philippines purchased seasonal vaccine beginning in 2011
(1608 per 100,000). In Thailand, the only other country to report
public sales data, private sales increased by .300% from 520,000
doses in 2008 to 2.2 million doses in 2009, and continued to
increase during 2010 (2.38 million doses) and 2011 (2.8 million
doses, Table 2). In 2011, combined private and public sector sales
in Thailand exceeded 7 million doses equal to 10,333 doses per
100,000 persons.
Pandemic Vaccine Use
Seven countries in our study used A(H1N1)pdm09 monovalent
vaccine during 2009 through 2010. All 6 lower-middle and low
income countries were eligible for vaccine donated by multina-
tional manufacturers and governments to WHO for global
distribution, but only Cambodia, Lao PDR, Myanmar and the
Philippines received A(H1N1)2009pdm monovalent vaccine [9].
Indonesia and Vietnam did not receive any A(H1N1)pdm09
vaccine despite being eligible for WHO donated vaccines. The
three high and upper-middle income countries of Singapore,
Malaysia and Thailand purchased A(H1N1)pdm09vaccine
(Table 2). The greatest number of vaccine doses received or
purchased per capita was in Singapore (25,560 per 100,000),
followed by Cambodia (19,189 per 100,000) and Lao PDR
(16,136 per 100,000).
Vaccine Guidelines and Program
Current global recommendations for seasonal influenza vaccine
include five groups: pregnant women, health care workers,
children 5 to 59 months, the elderly, and persons with high-risk
conditions. [8] Among these groups, pregnant women are listed as
the most important group.
Five countries, Indonesia, Malaysia, Singapore, Thailand and
Vietnam, all of which were high or middle income countries, had
issued guidelines for the use of seasonal influenza vaccines
(Table 3). Of the five countries with guidelines, two (40%)
recommended vaccination for pregnant women, four (80%) for
health care workers, three (60%) for young children, four (80%) for
elderly persons and three (60%) for persons with underlying
medical conditions. In addition, a number of other groups were
recommended for vaccination (Table 3).
Of the five countries with vaccine guidelines, three middle
income countries (Indonesia, Malaysia and Thailand) had
a seasonal influenza vaccination program in the public sector
with dedicated funding (Table 3). Malaysia said that justification
for vaccination was part of pandemic influenza preparedness. Both
Malaysia and Thailand said that data on influenza morbidity and
mortality were important factors in the decision to implement
a seasonal influenza vaccination policy. Thailand also said that
politics and pandemic preparedness were two additional factors.
Indonesia said their decision was based on the requirements for
the Hajj.
In-country Vaccine Capacity
Three middle income countries, Indonesia, Thailand and
Vietnam, reported developing in-country capacity for vaccine
production. In 2007 and again in 2009, as part of a global
initiative to transfer influenza vaccine technology to developing
countries, WHO, supported by funds from the U.S. Biomedical
Advanced Research and Development Authority (BARDA),
awarded funds to Indonesia ($3.5 million), Thailand ($4 million)
and Vietnam ($4.2 million) to complement local investments to
develop domestic vaccine production capacities [12]. Thailand’s
Government Pharmaceutical Organization is developing live-
attenuated monovalent and trivalent vaccine using a Russian seed
virus. Vietnam’s Institute of Vaccines and Medical Biologicals is
producing inactivated monovalent influenza vaccine. BioFarma
Indonesia acquired the technology to do fill and finish of seasonal
influenza vaccine and is obtaining technology for up-stream
processing and bulk production of antigen.
Discussion
The Southeast Asian countries included in our study differ
markedly in their demography, country income classification, and
economic resources allocated for healthcare. Despite these
differences, awareness of the importance of influenza prevention
is increasing in the region as demonstrated through established
influenza vaccine guidelines and increased influenza vaccine
distribution in the majority of countries. Thailand, an upper-
middle income country, and Singapore, a high income country,
had the highest rate of vaccines purchased in the private sector
since 2010. Indonesia, a lower-middle income country, reported
the lowest rates of public sector influenza vaccine purchase. For
the 10 countries combined, private sector sales during 2010 and
2011 (after the peak of the A(H1N1)pdm09 pandemic) exceeded
pre-pandemic sales during 2008. It is too early to know if this
positive effect of the A(H1N1)pdm09 pandemic on the demand for
seasonal influenza vaccine will continue in future years suggesting
a lasting influence. The only country reporting both private and
public sector sales, Thailand, exceeded 10,000 doses per 100,000
persons in 2011. For comparison, in the 2010–2011 influenza
season in the United States, 163 million doses of influenza vaccine
were distributed for a crude rate of 52,312/100,000 [13,14]. This
5-fold difference in the vaccine rate per capita between the two
countries would likely be smaller if the denominator in Thailand
were limited to the targeted risk groups. Nevertheless, it translates
into 52% population coverage in the United States vs. 10%
coverage in Thailand.
Vaccination guidelines varied substantially across ASEAN
countries and in only two countries did guidelines reflect current
global recommendations. [8] Most countries with national guide-
lines recommended vaccination of health care workers and elderly
persons, consistent with data from Southeast Asia and other
regions documenting the need to protect healthcare workers and
their patients as well as elderly persons at increased risk for severe
influenza [15,16,17]. In contrast, only two countries recom-
mended vaccination for pregnant women, WHO’s highest priority
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risk group, and only three countries recommended vaccination for
children aged 6–23 months, perhaps reflecting a need for more
evidence on these risk groups in the region or a lack of resources to
expand to these important risk groups. A recent study of influenza
vaccine in pregnant women in Bangladesh demonstrated a 63%
reduction in laboratory-confirmed influenza infections in infants of
vaccinated mothers and better outcomes for gestational age and
birth weight in infants [18,19]. Local data on disease burden,
seasonality, cost effectiveness, acceptability, coverage, and delivery
strategies are needed to inform development and implementation
of national vaccination strategies.
Receipt of A(H1N1)pdm09 pandemic vaccine correlated with
income classification, in that poorer countries were eligible for
donated vaccine and richer countries purchased vaccine. Howev-
er, receipt of pandemic vaccine generally did not correlate with the
scope of a country’s seasonal influenza vaccination policy. For
example, Cambodia does not have seasonal vaccination guidelines
but received a donation of 2.7 million doses of A(H1N1)pdm09
monovalent vaccine from WHO. In contrast, Vietnam, which has
broad influenza vaccination recommendations, opted against
using donated A(H1N1)pdm09 monovalent vaccine during the
pandemic. The country cited their regulation to perform quality
control testing of the vaccines prior to implementation as
a rationale for declining the donation.
Despite the widespread adoption of influenza vaccine recom-
mendations, the current amount of vaccine purchased in most
countries does not meet the needs of the identified target groups.
To address the growing need for more affordable and accessible
influenza vaccines during a pandemic, the World Health
Organization assisted eleven countries, including three middle
income countries in Southeast Asia (Indonesia, Thailand, and
Vietnam), in developing their domestic vaccine production
capacity [12]. Indonesia’s BioFarma collaborated with Japan’s
Biken Institute to develop local capacity. In July 2011, Thailand
licensed a locally-produced, live-attenuated monovalent pandemic
influenza vaccine and plans clinical trials on a trivalent influenza
vaccine. Finally, Vietnam completed the construction of
manufacturing plants for H5N1 and H1N1 vaccines in early
2011 and in April 2012 began a Phase I clinical trial for
monovalent H1N1 vaccine. Although these countries are still
several years away from commercial production of influenza
vaccines that could meet regional needs, progress is clearly
underway.
In the absence of locally available, affordable vaccine, lower
income countries wanting to introduce vaccine have few options.
In 2012, Lao PDR accepted 375,000 doses of seasonal influenza
vaccine donated by Walgreens Corporation, a U.S.-based
company [20]. This vaccine initiative represents an innovative
new public-private partnership, the first of its kind in Lao PDR
and perhaps a model for other countries in the region.
Our study has several limitations. First, because private sales
data were only provided in aggregate for several countries,
disparities in sales between these countries may have been hidden.
Second, vaccine sales data are not the same as vaccine uptake as
not all vaccines end up in a person’s arm. We did not account for
vaccine wastage which would result in lower per capita rates.
Third, our rate calculations did not account for the fact that
children may have received two doses and this would have
decreased the rates. Fourth, we did not limit the denominators to
the target groups which would have increased the rates. Finally,
private vaccine sales were underestimated because only three
multinational vaccine manufacturers were surveyed; the Thailand
FDA data are evidence of this.
We provide a summary of national influenza guidelines and
influenza vaccination sales for ASEAN countries. Although
vaccination sales remain generally low, consistent with global
findings [21], we document a regional change towards increased
vaccine sales. Advances in local vaccine production capacity in the
coming years may further increase regional availability of vaccine.
Public funding will be essential for national influenza vaccine
programs to continue to develop and grow in Southeast Asia. Only
Singapore and Thailand have vaccine recommendations that are
consistent with global standards, suggesting that more work is
needed to inform policy makers of data which support these
important global recommendations.
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